Are there more drugs approved? Is the regulatory pathway to getting a drug to market as a treatment for HD any easier? Has there been any improvement for patients affected with HD? Having been involved in Huntington’s disease clinical trials since 1999, QCTR’s Susan McGoldrick asks what has changed in this area over the last 15 years, and suggests how some of the pitfalls can be avoided.